Related Experiment Video
Updated: Jun 22, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
APOE gene polymorphisms and response to statin therapy.
E Zintzaras1, G D Kitsios, F Triposkiadis
1Department of Biomathematics, University of Thessaly School of Medicine, Larissa, Greece. zintza@med.uth.gr
The Pharmacogenomics Journal
|June 17, 2009
Summary
Apolipoprotein E (APOE) gene variants do not significantly alter lipid responses to statin therapy. This meta-analysis suggests APOE genetic testing is not currently recommended for guiding statin treatment decisions.
Area of Science:
- Pharmacogenomics
- Cardiovascular Genetics
- Lipid Metabolism
Background:
- Inconsistent findings exist regarding the influence of Apolipoprotein E (APOE) gene variants on lipid responses to statin medications.
- Understanding these genetic influences is crucial for personalized cardiovascular disease management.
Purpose of the Study:
- To conduct a meta-analysis estimating the lipid response to statin treatment across different APOE genetic variants (e2, e3e3, e4).
- To determine if APOE genotypes significantly impact the effectiveness of statins in modifying lipid profiles.
Main Methods:
- A meta-analysis was performed, synthesizing data from twenty-four published studies.
- Pooled mean reductions in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides were calculated for each APOE genotype group.
Main Results:
- Statins significantly reduced TC across all APOE variants (e2 carriers: -27.7%, e3e3 homozygotes: -25.3%, e4 carriers: -25.1%).
- Significant changes in LDL-C, HDL-C, and triglycerides were observed for all genotypes, but no significant differences were found among the genotypic groups.
- Substantial heterogeneity was present among the included studies.
Conclusions:
- APOE genotypes do not appear to significantly modulate the lipid-lowering effects of statin therapy.
- Current evidence suggests limited clinical utility for APOE genetic testing in guiding statin treatment selection or predicting response.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...